May 13, 2013 11:22 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Monday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Pharmaceuticals Holdings (NASDAQ: ENDP), but lowered the price target from $47.00 to $37.00.In the report, Davis noted, “We were wrong, FDA acted irrationally inconsistent, in our view, and will allow crushable Opana generics to flood the market despite blocking crushable OxyContins. ENDP now expects more Gx approvals and slashed guidance. This is disappointing & material but we think ENDP has underappreciated spending flexibility (meaningful restructuring unveiled by Q2 results at latest) and new mgmt will be aggressive on the BD front.”Endo Pharmaceuticals Holdings closed on Friday at $34.97.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.